Merck Accelerates Portfolio Transformation Amid Strong Q2 Results
Merck & Co., Inc. () reported its second-quarter 2026 financial results on August 4, 2026, demonstrating accelerating progress in its portfolio transformation strategy.
The company's worldwide sales reached $16.6 billion, up 5% on a nominal basis and 4% excluding foreign exchange, while beating Wall Street earnings expectations despite a significant acquisition-related charge.
Merck's expanding pipeline of over 20 growth drivers targets more than $70 billion in mid-2030s revenue opportunity, with multiple products showing strong commercial uptake. The company's Human Health segment generated $14.8 billion in sales, up 5% year-over-year and 4% excluding foreign exchange effects.
The quarter showcased 'increasing contributions from new launches' as Merck works to reduce its dependence on KEYTRUDA ahead of eventual patent expiration. Launch product revenue reached $1.5 billion in Q2 2026, more than doubling from $0.6 billion in the prior-year quarter.